Our editorial team's signature event is now established as our own Diabetes Care Symposium at the ADA Scientific Sessions with the 4th Annual Diabetes Care Symposium being presented at the 75th Scientific Sessions in June 2015 (in Boston, MA). Each year, we attempt to refine the format and content of this event. In June 2014, we revised the format by dividing it into two 1-h sessions and selecting overarching themes. The first segment was designed to introduce a novel twist with a presentation entitled "Best of Diabetes Care." Its purpose was to provide brief overviews of several articles felt by the Associate Editors to be some of the most noteworthy original research reports published in Diabetes Care during the past year. That segment of the program received rave reviews, so we continued the format in the 2015 symposium. The topics for this year's "Best of Diabetes Care" included updates on clinical phenotypes and epidemiology, depression in diabetes, and hypertension/nephrology.
The second segment of this year's program had presentations from the four selected original articles from our competition focusing on "Novel Clinical Interventions in Therapy That Impact the Management of Diabetes." These articles are featured in this issue. The presentations included a study evaluating a novel approach to glycemic control with use of an antianginal drug (i.e., ranolazline) in subjects with type 2 diabetes and a study evaluating a novel sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor as adjunctive treatment for type 1 diabetes (13, 14) . We also presented two studies that provided updates on the development of the artificial pancreas, the first evaluating the safety and efficacy of the fully integrated Medtronic hybrid closed-loop system in a type 1 diabetes camp and the second offering insights on predictive low-glucose suspension and nocturnal hypoglycemia in children (15, 16) . The success of the symposium at the ADA Scientific Sessions has also fostered interest for such a symposium at the upcoming International Diabetes Federation's World Diabetes Congress, 30 November-4 December 2015, in Vancouver, Canada. Those articles will be published in a special symposium section in the January 2016 issue of Diabetes Care.
The most innovative feature of this year's ADA's symposium, however, was the recognition of those individuals who have recently been featured in our Profiles in Progress initiative. Several times a year Diabetes Care publishes an article honoring a researcher or health care professional who has made notable contributions in the field of diabetes and served as a role model and mentor for many of our readers. In a brief ceremony this year, we recognized Drs. Samuel Rahbar, Christopher Dyer Saudek, George S. Eisenbarth, Gerald M. Reaven, Frederick C. Goetz, Oscar B. Crofford, Saul Genuth, and James R. Gavin III (17) (18) (19) (20) (21) (22) (23) (24) . Finally, at each annual ADA Scientific Sessions, we also hold our Diabetes Care Editors' Expert Forum and publish its proceedings.
Another innovative strategy for our journal has been to devote a portion of selected issues to a specific focus, either as multiple reports from landmark studies (e.g., the TODAY Study [25] and DCCT/EDIC [26] ) or to highlight a specific clinical and research focus (e.g., artificial pancreas [27] and diabetes prevention [28] ) ( Table 2 ). The past 6 months have seen incredibly important special issues. Specifically, our February 2015 issue was devoted to understanding and addressing disparities in access to diabetes care and the focus of research (29). The topics covered ranged from the impact of community health worker-led interventions, to a possible role of language barriers in diabetes complications, to cerebral structural changes associated with diabetic kidney disease in African Americans, and to racial differences in underlying pathophysiologic mechanisms (29). Our March 2015 issue described research related to novel combinations of SGLT1 blockers with insulin, dipeptidyl peptidase-4 inhibitors, or other therapies; favorable effects of (31) . This issue had contributions from leaders in the field and described research related to the present status of treatment methods and clinical outcomes in type 1 diabetes in the U.S.; discussed current concepts on pathogenesis, prediction, and prevention of the disease; reviewed the successes and ongoing challenges of islet transplantation; and described a pathway for the translation of advances in diabetes technology into an artificial pancreas suitable for home use by large numbers of patients (31) . We will continue to present special topics in our monthly issues, based on the positive responses from our readers. We are also very pleased with responses to our state-of-the-art Reviews, Bench to Clinic Symposia, and Perspectives in Care. Topics of these feature articles have in the past year included patient preferences for noninsulin diabetes medications (32) , the association between diabetes and depression (33), the challenges for people with diabetes at high altitude (34), natriuretic peptides (35), hyperosmolar hyperglycemic states (36) , and dipeptidyl peptidase-4 inhibitors and microvascular complications (37) . A comprehensive review on the SEARCH for Diabetes in Youth study, for which major findings were highlighted and future directions identified for this important cohort was published in December 2014 (38) . We recently added to this list a fascinating discussion of the role of the gut microbiome (39) and provided what is felt to be the most upto-date review on the evaluation and treatment of obesity in type 2 diabetes (40) .
We also continue to feature debates in a Point-Counterpoint format. In an elegant debate this past year, Dr. Abrahamson provided his argument suggesting that avoiding use of sulfonylureas as a class of medication as an add-on to metformin is not appropriate as there are many patients whose glycemic control would improve with use of these drugs with minimal risk of adverse events (41) . In the counterpoint narrative, Dr. Genuth suggested there is no longer a need for sulfonylureas to remain a first-line addition to metformin for those patients whose clinical characteristics are appropriate and whose health insurance and/ or financial resources make an alternative drug affordable (42) .
In closing, to our editorial team, Diabetes Care is a living thing, alive and growing, and is also getting better over time. We take pride in every issue, pay attention to every submission, and continue to strive for improvement. The bar for acceptance of manuscripts has steadily risen and, to the chagrin of many authors, our rejection rate continues to climb.
So, in getting back to the original question asked in July 2014dCan it possibly get any better than this?dwe think we know the answer and will continue to focus on the future through new challenges, new concepts, and new measures. 
